Julie R. Brahmer, MD

Articles

Clinical Pearls and Closing Thoughts on NSCLC Treatment Landscape

October 10th 2023

Closing out their discussion on biomarker testing and targeted therapies in non–small cell lung cancer, the panel of expert oncologists share clinical pearls and thoughts on the evolving treatment landscape.

Emerging Targets in Non–Small Cell Lung Cancer

October 10th 2023

Julie R. Brahmer, MD, details emerging targets in non–small cell lung cancer and the outlook for the future of treatment.

Treating MET Exon 14 NSCLC

October 3rd 2023

The focus turns to therapeutic strategies for treating MET exon 14 non–small cell lung cancer.

Approach to Treating Patients with NSCLC and RET Fusions

October 3rd 2023

Experts on non–small cell lung cancer share their approaches to treating patients who have RET fusions and review updates on selpercatinib and pralsetinib.

Dr Brahmer on the Investigation of FLX475 in NSCLC

October 3rd 2023

Julie Renee Brahmer, MD, discusses the investigation of FLX475 in patients with advanced non–small cell lung cancer.

Treatment of NTRK Fusions in NSCLC

September 26th 2023

Julie R. Brahmer, MD, and Joshua K. Sabari, MD, review recent data on entrectinib and larotrectinib for the treatment of patients with NSCLC with NTRK fusions.

Choosing Between ALK Inhibitors in the Treatment of NSCLC

September 26th 2023

The expert panel discusses factors that influence treatment decisions when choosing appropriate therapy for patients with ALK-rearranged NSCLC.

Emerging Treatment Options for Patients with NSCLC with ALK Rearrangements

September 19th 2023

Experts on non–small cell lung cancer discuss recent data on brigatinib and lorlatinib for the treatment of patients with ALK rearrangements.

Is There a Role for Immunotherapy in Patients with KRAS G12C-Mutant NSCLC and STK11 or KEAP1 Co-Mutations?

September 19th 2023

Luis Raez, MD, offers insights on how co-mutations in STK11 or KEAP1 impact the use of immunotherapies in KRAS G12C–mutant non–small cell lung cancer.

Adagrasib for Patients with KRAS G12C–Mutant NSCLC

September 12th 2023

Joshua K. Sabari, MD, discusses adagrasib as a treatment of patients with NSCLC with KRAS G12C mutations, and provides insight on treating patients who have progressed on prior KRAS G12C inhibitors.

Sotorasib in the Treatment of KRAS G12C–Mutant NSCLC

September 12th 2023

Expert panelists review the CodeBreaK trials focused on sotorasib in the treatment of patients with KRAS G12C-mutant non–small cell lung cancer.

NSCLC With Uncommon EGFR Mutations: First-Generation EGFR TKIs and Role of Immunotherapy

September 5th 2023

Shared insight on the use of first-generation EGFR tyrosine kinase inhibitors and the role of immunotherapy in treating patients with NSCLC with uncommon EGFR mutations.

Choosing Treatments for Patients with NSCLC with Uncommon EGFR Mutations

September 5th 2023

Julie R. Brahmer, MD, discusses treatment considerations when choosing between afatinib and osimertinib in patients with NSCLC with rare EGFR mutations.

Treatment Options for Patients with NSCLC with EGFR Mutations

August 29th 2023

Key opinion leaders on non–small cell lung cancer review treatment options for patients with EGFR mutations.

Strategies to Improve Biomarker Testing in NSCLC

August 29th 2023

Experts on non–small cell lung cancer discuss strategies to improve molecular testing and opportunities for community physicians to reach out to expert oncologists for clinical insights.

Biomarker Testing Patterns in Academic and Community Settings Treating NSCLC

August 22nd 2023

Antonia Sepulveda, MD, PhD, an expert on NSCLC, outlines discrepancies in molecular testing between academic and community settings.

NSCLC: Biomarker Testing Strategies and Turnaround Time

August 22nd 2023

Focused discussion on tissue testing and the effect of turnaround time on NSCLC treatment and molecular testing strategies.

Liquid vs Tissue Biopsies in NSCLC

August 15th 2023

Expert oncologists compare the logistics and sensitivities of liquid and tissue biopsies in the treatment of non–small cell lung cancer.

Biomarker Testing in Non-Small Cell Lung Cancer

August 15th 2023

A panel of experts on the treatment of non–small cell lung cancer (NSCLC) discuss the role of biomarker testing and review testing strategies.

Dr Brahmer on First-line Tremelimumab/Durvalumab Plus Chemotherapy in NSCLC

March 23rd 2023

Julie Renee Brahmer, MD, discusses the use of tremelimumab plus durvalumab and platinum-based chemotherapy for the first-line treatment of patients with non–small cell lung cancer, and how decisions can be made between this regimen and nivolumab plus ipilimumab and chemotherapy.